Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: A phase II trial (CALGB 8944)

Breast Cancer Research and Treatment

Volumn 113, Issue 3, 2009, Pages 479-490

  Kimmick, G G ^a   Cirrincione, C ^a   Duggan, D B ^b   Bhalla, K ^c   Robert, N ^d   Berry, D ^e   Norton, L ^f   Lemke, S ^b   Henderson, I C ^g   Hudis, C ^f   Winer, E ^h,i  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d INOVA FAIRFAX HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ Cancer and Leukemia Group B   (United States)

Author keywords

Breast cancer; Chemotherapy; Locally advanced; Long term follow up; Neoadjuvant; Stage III

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DIARRHEA; DYSPHAGIA; DYSPNEA; ESOPHAGITIS; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HEMATURIA; HUMAN; INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MASTECTOMY; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; METHOTREXATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS;

EID: 58549118451     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9943-2     Document Type: Article

References (45)

1. M Perloff GJ Lesnick A Korzun 1988 Combination chemotherapy with mastectomy or adiotherapy for stage-III breast-carcinoma-a Cancer and Leukemia Group-B Study J Clin Oncol 6 261 269
2. SM Swain RA Sorace CS Bagley 1987 Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer Cancer Res 47 3889 3894
3. M Colozza S Gori P Anastasi 1996 Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results Am J Clin Oncol 19 10 17
4. J Rouesse S Friedman D Sarrazin 1986 Primary chemotherapy in the treatment of inflammatory breast-carcinoma-a study of 230 cases from the Institut-Gustave-Roussy J Clin Oncol 4 1765 1771
5. RD Cummiskey R Mera EA Levine 1998 Preoperative chemotherapy for locally advanced breast carcinoma at Charity Hospital, New Orleans, Louisiana Am Surg 64 103 106
6. A Eltahir SD Heys AW Hutcheon 1998 Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy Am J Surg 175 127 132
7. JD Cunningham SE Weiss S Ahmed 1998 The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer Cancer Invest 16 80 86
8. RB Jones JF Holland S Bhardwaj L Norton C Wilfinger A Strashun 1987 A phase I-II study of intensive-dose adriamycin for advanced breast cancer J Clin Oncol 5 172 177
9. BL Tranum B McDonald T Thigpen 1982 Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study Cancer 49 835 839
10. GN Hortobagyi AU Buzdar GP Bodey 1987 High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study J Clin Oncol 5 178 184
11. G Bonadonna M Zambetti P Valagussa 1995 Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results JAMA 273 542 547
12. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457
13. DR Cox 1972 Regression models and life tables (with discussion) J R Stat Soc 34 187
14. JR Anderson KC Cain RD Gelber 1983 Analysis of survival by tumor response J Clin Oncol 1 710 719
15. G Bonadonna P Valagussa C Brambilla 1998 Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute J Clin Oncol 16 93 100
16. HM Kuerer LA Newman TL Smith 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469
17. JP Ferriere I Assier H Cure 1998 Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome Am J Clin Oncol 21 117 120
18. MR Machiavelli AO Romero JE Perez 1998 Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma Cancer J Sci Am 4 125 131
19. TJ Powles TF Hickish A Makris 1995 Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer J Clin Oncol 13 547 552
20. JA van der Hage CJ van de Velde JP Julien M Tubiana-Hulin C Vandervelden L Duchateau 2001 Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 4224 4237
21. R Rouzier JM Extra J Klijanienko 2002 Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes J Clin Oncol 20 1304 1310
22. PM Ravdin HA Burris G Cook 1995 Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer J Clin Oncol 13 2879 2885
23. V Valero FA Holmes RS Walters 1995 Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer J Clin Oncol 13 2886 2894
24. IC Henderson DA Berry GD Demetri 2003 Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976 983
25. ML Citron DA Berry C Cirrincione 2003 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741 J Clin Oncol 21 1431 1439
26. BT Hennessy GN Hortobagyi R Rouzier 2005 Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy J Clin Oncol 23 9304 9311
27. SW Beenken MM Urist Y Zhang 2003 Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer Ann Surg 237 732 738
28. DR McCready GN Hortobagyi SW Kau TL Smith AU Buzdar CM Balch 1989 The prognostic-significance of lymph-node metastases after preoperative chemotherapy for Locally advanced breast-cancer Arch Surg 124 21 25
29. B Fisher J Bryant N Wolmark 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685
30. JY Pierga E Mouret V Dieras 2000 Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer Br J Cancer 83 1480 1487
31. HD Bear S Anderson RE Smith 2006 Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 2019 2027
32. HD Bear S Anderson A Brown 2003 The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21 4165 4174
33. G Bonadonna U Veronesi C Brambilla 1990 Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more J Natl Cancer Inst 82 1539 1545
34. B Fisher J Bryant N Wolmark 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685
35. ER Fisher J Wang J Bryant B Fisher E Mamounas N Wolmark 2002 Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18 Cancer 95 681 695
36. G von Minckwitz G Raab A Caputo 2005 Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group J Clin Oncol 23 2676 2685
37. M Colleoni G Viale D Zahrieh 2004 Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 6622 6628
38. IF Faneyte JG Schrama JL Peterse PL Remijnse S Rodenhuis MJ van de Vijver 2003 Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br J Cancer 88 406 412
39. AU Buzdar V Valero R Theriault 2003 Pathologic complete response to chemotherapy is related to hormone receptor status Breast Cancer Res Treat 82 69S
40. V Guarneri K Broglio SW Kau 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 1037 1044
41. AE Ring IE Smith S Ashley LG Fulford SR Lakhani 2004 Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer 91 2012 2017
42. SD Merajver BL Weber R Cody 1997 Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience J Clin Oncol 15 2873 2881
43. WG Cance LA Carey BF Calvo 2002 Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival Ann Surg 236 295 302
44. DA Berry C Cirrincione IC Henderson 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 1658 1667
45. B Fisher EP Mamounas 1995 Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer J Clin Oncol 13 537 540